With A New Director Elect, NICE Is On A Mission To Elevate Medtech
A refreshed NICE, soon to get a new medtech director, has set out a series of priorities that show an intent to bring medtech closer to the center of its activities.
You may also be interested in...
NICE’s early value assessment (EVA) pilot for medtech will have failed unless it changes the way that medical devices “as a whole” are evaluated in the UK, according to Mark Chapman, the organization’s interim director of medical technology.
Evolving health care demands, digital innovation and the need to work within tighter budgets have prompted the UK’s NICE to reset its strategy for the coming five years.
The “what” and the “how” involved in bringing medical technology to market for adoption by health-care systems is changing fast. The UK is laying the groundwork to be a global medtech innovation champion with two new tools: NHS England’s Long Term Plan and the newly boosted Accelerated Access Collaborative. The AAC's first chief executive, Sam Roberts, has been profiling her role in this prospective UK market access transformation.